SpringWorks Therapeutics (SWTX) Competitors $35.59 +0.81 (+2.33%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SWTX vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, NUVL, LEGN, BPMC, and ELANShould you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. SpringWorks Therapeutics vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health SpringWorks Therapeutics (NASDAQ:SWTX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment. Does the MarketBeat Community favor SWTX or QGEN? Qiagen received 150 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 70.21% of users gave SpringWorks Therapeutics an outperform vote while only 60.88% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformSpringWorks TherapeuticsOutperform Votes9970.21% Underperform Votes4229.79% QiagenOutperform Votes24960.88% Underperform Votes16039.12% Does the media refer more to SWTX or QGEN? In the previous week, Qiagen had 2 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 6 mentions for Qiagen and 4 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.94 beat Qiagen's score of 0.47 indicating that SpringWorks Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SpringWorks Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate SWTX or QGEN? SpringWorks Therapeutics presently has a consensus price target of $69.50, suggesting a potential upside of 95.28%. Qiagen has a consensus price target of $51.88, suggesting a potential upside of 16.13%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe SpringWorks Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Qiagen 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more risk & volatility, SWTX or QGEN? SpringWorks Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Do institutionals & insiders have more ownership in SWTX or QGEN? 70.0% of Qiagen shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is SWTX or QGEN more profitable? Qiagen has a net margin of 4.73% compared to SpringWorks Therapeutics' net margin of -203.09%. Qiagen's return on equity of 13.43% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-203.09% -48.21% -42.19% Qiagen 4.73%13.43%8.10% Which has stronger earnings & valuation, SWTX or QGEN? Qiagen has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$135.49M19.54-$325.10M-$3.88-9.17Qiagen$1.97B5.18$341.30M$0.39114.54 SummaryQiagen beats SpringWorks Therapeutics on 11 of the 17 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SWTX vs. The Competition Export to ExcelMetricSpringWorks TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$2.94B$5.07B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-9.1745.9499.0517.15Price / Sales19.54411.851,121.17116.80Price / CashN/A182.1041.5237.88Price / Book3.563.894.754.78Net Income-$325.10M-$42.21M$119.33M$225.60M7 Day Performance-7.08%-2.14%-1.86%-1.23%1 Month Performance-1.96%4.21%11.40%3.07%1 Year Performance6.59%18.39%30.26%16.48% SpringWorks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SWTXSpringWorks Therapeutics2.0141 of 5 stars$35.59+2.3%$69.50+95.3%+11.3%$2.59B$135.49M-9.17305Positive NewsQGENQiagen3.7415 of 5 stars$45.47+0.2%$51.15+12.5%+3.1%$10.38B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0406 of 5 stars$84.49+1.8%$97.23+15.1%+27.8%$8.96B$612.78M-95.91560ROIVRoivant Sciences3.0012 of 5 stars$12.08+2.0%$17.93+48.4%+16.2%$8.79B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1403 of 5 stars$136.50+5.1%$191.77+40.5%+12.6%$8.28B$327.43M-16.52640RVMDRevolution Medicines4.5467 of 5 stars$44.90-0.2%$63.67+41.8%+71.5%$7.55B$11.58M-12.54443Insider TradeLNTHLantheus4.3768 of 5 stars$94.84+2.0%$130.00+37.1%+53.4%$6.59B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1959 of 5 stars$86.65-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive NewsLEGNLegend Biotech1.553 of 5 stars$33.53-4.5%$81.54+143.2%-43.2%$6.12B$520.18M-36.971,800BPMCBlueprint Medicines2.5727 of 5 stars$95.29+2.3%$122.11+28.1%+7.2%$6.05B$434.42M-45.28640Insider TradeELANElanco Animal Health3.779 of 5 stars$12.19+0.7%$16.75+37.4%-17.0%$6.03B$4.45B30.259,300 Related Companies and Tools Related Companies Qiagen Competitors Intra-Cellular Therapies Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Lantheus Competitors Nuvalent Competitors Legend Biotech Competitors Blueprint Medicines Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SWTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
